Blood Proteins as an Aging Clock: The Proteomic Panel Coming for Methylation

The work, led by a team including Alexey Moskalev — a familiar name in longevity research — did something unfashionably methodical. Rather than launch yet another proprietary clock, the authors pooled 17 publicly available plasma proteomics datasets and asked a simple question: which proteins keep showing up as associated with aging, across studies, across cohorts, across mass-spec platforms? The result is an integrated list of candidates, ranked by how reliably they can actually be detected in human plasma by mass spectrometry — a practical filter that matters enormously if the goal is a test that runs in a real clinical lab rather than a one-off academic showcase. The authors propose this consensus list as the scaffolding for a future proteomic aging clock.

Why proteins, and why now? Epigenetic clocks have been transformative, but they have known limitations. They measure regulatory state — what your cells are set up to do — rather than what your body is currently doing. Proteins are closer to the action: they carry inflammatory signals, ferry lipids, repair tissues, and clean up debris. If aging is fundamentally a story of slow systemic dysregulation, the proteome is where that story is being narrated in real time.

Two biological themes dominate the proteins that survived the review's filter: inflammation and lipid metabolism. That is not a surprise to anyone tracking the longevity literature — chronic low-grade inflammation ("inflammaging") and shifting lipid handling are among the most replicated hallmarks of biological aging. But the review's framing is novel in a specific way: it argues, for the first time at this scale, that proteins already associated with overt systemic disease — including some with FDA-approved clinical uses — may double as markers of the aging process itself.

That is a subtle but important reframing. It suggests the boundary between "disease biomarker" and "aging biomarker" is more porous than the field has often assumed. A protein elevated in cardiovascular risk panels may not just signal disease — it may be reading out the same underlying drift that is making the rest of you older. If that holds up under prospective validation, it means parts of the proteomic aging clock could be built from assays that already exist in hospital chemistry labs.

To be clear about where the evidence sits: the review is a synthesis, not a head-to-head trial. It proposes a panel; it does not yet demonstrate that this panel beats GrimAge or PhenoAge at predicting mortality, healthspan, or response to interventions. That work is still to come. What it offers is a credible, transparent starting point — built from public data, filtered for analytical feasibility — that other groups can now stress-test in independent cohorts.

Methylation clocks have a head start of more than a decade and an enormous validation literature behind them. Proteomic clocks have an arguably better mechanistic story: proteins are closer to phenotype, more responsive to interventions on a meaningful timescale, and — once a target panel is locked — measurable by targeted mass spectrometry or immunoassays without sequencing infrastructure. The honest answer to "which one wins?" is that they will likely coexist, and the most informative consumer tests of the next few years will probably blend signals from both.

For readers who already order biological-age tests, the practical near-term implication is patience. The consensus protein list is a research blueprint, not a product. No validated consumer proteomic clock built on this specific panel exists yet, and any company that markets one in the next year should be asked, politely but firmly, to show its validation cohort, its test-retest reliability, and its mortality or healthspan associations in independent data. "Built on a systematic review" is not the same as "validated against outcomes."

The longer-term implication is more interesting. If proteomic clocks mature along the trajectory this review sketches, biological-age testing could shift from a niche, mail-order curiosity to something more like a standard panel — measured on equipment hospitals already own, anchored to proteins clinicians already recognize, and updated frequently enough to actually track whether a lifestyle change, a drug, or an intervention is moving the needle. Decisions about your health, of course, belong with a clinician who knows your full picture, not a dashboard.

The bigger picture is that aging biology is finally producing the kind of layered, multi-omic measurement infrastructure it has long needed. Methylation gave the field its first reliable yardstick. Proteomics may give it the second — one that speaks the same language as the rest of clinical medicine, and that, in time, could make "how old is my body actually behaving?" a question with a careful, quantitative, and useful answer.